| Q35796700 | A Fab-Selective Immunoglobulin-Binding Domain from Streptococcal Protein G with Improved Half-Life Extension Properties |
| Q30420026 | A hybrid protein-polymer nanoworm potentiates apoptosis better than a monoclonal antibody |
| Q36026775 | A novel recombinant slow-release TNF α-derived peptide effectively inhibits tumor growth and angiogensis |
| Q37722693 | A novel selective VPAC2 agonist peptide-conjugated chitosan modified selenium nanoparticles with enhanced anti-type 2 diabetes synergy effects |
| Q35146077 | A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity |
| Q41504457 | ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody |
| Q34760439 | Albumin fusion of interleukin-28B: production and characterization of its biological activities and protein stability. |
| Q35942344 | Albumin-binding domain conjugate for near-infrared fluorescence lymphatic imaging |
| Q30420582 | Analysis of the relationship between end-to-end distance and activity of single-chain antibody against colorectal carcinoma |
| Q37187003 | Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. |
| Q38712817 | Binding and biologic characterization of recombinant human serum albumin-eTGFBR2 fusion protein expressed in CHO cells |
| Q37377633 | Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives |
| Q90212066 | Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells |
| Q49195146 | Bispecific antibodies: design, therapy, perspectives |
| Q90183571 | Brolucizimab-leading an era of structural revolution for long-term VEGF suppression |
| Q30360904 | CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications. |
| Q35108395 | Comparative study of somatostatin-human serum albumin fusion proteins and natural somatostatin on receptor binding, internalization and activation |
| Q39540318 | Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding |
| Q90211949 | David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments |
| Q90312396 | Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer |
| Q39675238 | Extending the half-life of a fab fragment through generation of a humanized anti-human serum albumin Fv domain: An investigation into the correlation between affinity and serum half-life |
| Q34695496 | FGF21 can be mimicked in vitro and in vivo by a novel anti-FGFR1c/β-Klotho bispecific protein |
| Q37327316 | Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding |
| Q34550963 | Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds |
| Q42371513 | Generation and evaluation of antibody agents for molecular imaging of CD44v6-expressing cancers |
| Q33480823 | Generation of novel single-chain antibodies by phage-display technology to direct imaging agents highly selective to pancreatic beta- or alpha-cells in vivo |
| Q35047652 | Generation of “LYmph Node Derived Antibody Libraries” (LYNDAL) for selecting fully human antibody fragments with therapeutic potential |
| Q35552397 | Genetically engineered humanized mouse models for preclinical antibody studies |
| Q89967469 | Getting CD19 Into Shape: Expression of Natively Folded "Difficult-to- Express" CD19 for Staining and Stimulation of CAR-T Cells |
| Q37388409 | Human monoclonal antibodies and engineered antibody domains as HIV-1 entry inhibitors |
| Q38343221 | Humanization of a mouse monoclonal antibody directed against a cell surface-exposed epitope of membrane-associated heat shock protein 70 (Hsp70). |
| Q38116457 | IL-1Ra and its delivery strategies: inserting the association in perspective. |
| Q58562368 | Impact of Buffers on Colloidal Property and Aggregation Propensities of a Bispecific Antibody |
| Q34724092 | Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain |
| Q30393523 | Molecular Imaging of Pancreatic Cancer with Antibodies |
| Q47221249 | Novel, Anti-hTNF-α Variable New Antigen Receptor Formats with Enhanced Neutralizing Potency and Multifunctionality, Generated for Therapeutic Development |
| Q38208275 | Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases |
| Q89422301 | Overview of Antibody Drug Delivery |
| Q37138252 | Pharmacokinetic properties of IgG and various Fc fusion proteins in mice |
| Q41224752 | Plasma half-life extension of small recombinant antibodies by fusion to immunoglobulin-binding domains |
| Q37207310 | Radionuclide-Based Cancer Imaging Targeting the Carcinoembryonic Antigen. |
| Q41696278 | Recent advances of bispecific antibodies in solid tumors |
| Q36507229 | Recombinant HSA-CMG2 Is a Promising Anthrax Toxin Inhibitor |
| Q39939991 | Redirecting NK cells mediated tumor cell lysis by a new recombinant bifunctional protein. |
| Q37778732 | Research and development of next generation of antibody-based therapeutics |
| Q92538845 | Selective Engagement of FcγRIV by a M2e-Specific Single Domain Antibody Construct Protects Against Influenza A Virus Infection |
| Q34420356 | Selective delivery of interleukine-1 receptor antagonist to inflamed joint by albumin fusion |
| Q47554821 | Single-Domain Antibodies As Therapeutics against Human Viral Diseases |
| Q42557601 | Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics |
| Q33335367 | Substantially improved pharmacokinetics of recombinant human butyrylcholinesterase by fusion to human serum albumin |
| Q39659408 | The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein |
| Q42323236 | The making of bispecific antibodies |
| Q37491236 | Therapeutic antibodies: successes, limitations and hopes for the future |
| Q89700506 | Therapeutic potential of an anti-HER2 single chain antibody-DM1 conjugates for the treatment of HER2-positive cancer |
| Q34109974 | Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins |
| Q27027238 | Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics |